The University of Notre Dame’s Broome campus-based Nulungu Research Institute has appointed Professor Jeanette Ward as Adjunct Professor to its teaching and research team. Nulungu is one of three research institutes of the UND. Professor Ward holds the position of Consultant, Public Health Medicine with WA Country Health Services and this adjunct appointment aims to further strengthen the connection between Nulungu and health service providers in the Kimberley region. Her role with WA Country Health Services focuses on strategic development of public health, primary health care and stakeholder partnerships to improve population outcomes. Professor Ward will work with Nulungu and the Notre Dame Fremantle campus-based Institute for Health Research (IHR) to undertake “collaborative research, implementation projects and higher-degree student supervision in ways that promote academic support for Aboriginal community re-empowerment and evaluate the effectiveness of strategies to shift control from distant institutions to local governance structures and partnership”, said Nulungu’s director, Associate Professor Sandra Wooltorton. “Subsidiarity as an organisational principle will be explored in this work. As an academic institution, Nulungu fosters Aboriginal intellectual traditions, according respect and recognition of ownership of Country, Aboriginal Knowledges, continuing cultural practice and cultural governance. This further acknowledges the cultural heritage that underpins contemporary community actions to create a better future for the people of the Kimberley and beyond. Nulungu’s guiding principle is to work with ‘Right People, Right Country, Right Way’,” she said.
Researchers at Monash University and the Hudson Institute of Medical Research have received a highly competitive Victoria Cancer Agency (VCA) grant worth $2 million to determine whether particular prostate and colorectal cancer patients will respond to a new class of cancer drug known as BET inhibitors. Unlike chemotherapy which indiscriminately attacks ‘good’ and ‘bad’ cells, BET inhibitors — a type of epigenetic therapy — work on a genetic level to turn off the growth of cancer cells. Lead researcher is Dr Arun Azad, Senior Research Fellow at Monash University and Consultant Medical Oncologist at Monash Health. The collaborative research project builds on the previous work of Hudson Institute’s Associate Professor Ron Firestein, who identified the RNA biomarker and potential benefit of BET inhibitors in pre-clinical models in his previous laboratory at Genentech Inc. Undertaken at Monash Health, the trial will recruit 25 patients with advanced prostate or colorectal cancer and for whom other treatments options have failed. Co-collaborators on this study include Monash University’s Professor Gail Risbridger, Associate Professor Helen Abud, colorectal surgeon Associate Professor Paul McMurrick and Cabrini’s Dr Simon Wilkins.
Four members of Flinders University’s School of Medicine, Nursing and Health Sciences have received 2016 Vice-Chancellor Awards for Early Career Researchers. Dr Kate Laver, from the School of Health Sciences, aims to take evidence-based interventions for people with dementia into their homes using telehealth technologies. Dr Amanda Muller (School of Nursing and Midwifery), supports the language needs of over 500 international nursing students at Flinders, delivering face-to-face classes and providing online support. She also researches English for Specific Purposes (Nursing English and Academic English) and the use of computer games to teach language. Dr Andrew Vakulin’s (Medicine) current research focus is the exploration of novel neurophysiological, neurobehavioural and biological measures or “biomarkers” that may be useful in clinically identifying individual patients who may be more vulnerable to sleepiness-related impairments and accident risk, as well as the efficacy of sleep apnoea treatments. Dr Annabelle Wilson (Health Sciences) has worked with Aboriginal people both as a dietitian and a researcher in urban, rural and remote communities across Australia.
New South Wales’ first full undergraduate medical degree in a regional centre will be offered in Port Macquarie next year, the President and Vice-Chancellor of University of NSW Ian Jacobs has announced. Developing a full undergraduate medical degree was a key component of a collaborative project announced in 2011 between UNSW, the University of Newcastle and North Coast Institute of TAFE. The project secured $20 million in federal funding for a purpose-built facility, the Port Macquarie Shared Health Research and Education Campus (SHREC). UNSW currently provides medical education for 4 years of a medical degree — Years 3 to 6 — through its Rural Clinical School campuses in Port Macquarie, Coffs Harbour, Albury, Griffith and Wagga Wagga. Dean of UNSW Medicine Professor Rodney Phillips said the Faculty had undertaken an assessment of the new facility and what needed to be in place to offer the full 6-year program.
Clinical training for University of Queensland medical and allied health students will be boosted with the opening of student training centres at the Queen Elizabeth II Jubilee and Redland hospitals. UQ Vice-Chancellor Professor Peter Høj said the new facilities would “revolutionise” training practices at the hospitals and offer more clinical placement opportunities for students. The training centres have been built with $2.2 million from the Federal Government Health Workforce Australia Fund and $1.15 million from UQ, on hospital campus sites provided by the State Government’s Metro South Hospital and Health Service. About 300 UQ medical students rotate through the Redland and QEII Jubilee hospitals each year for specialist training in medicine, surgery, gynaecology and critical care disciplines. A further 100 students from other UQ schools rotate through the sites for clinical training in areas such as physiotherapy, occupational therapy and pharmacy.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.